U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSIGLITAZONE

SMILES

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3

InChI

InChIKey=YASAKCUCGLMORW-UHFFFAOYSA-N
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

HIDE SMILES / InChI
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/rosiglitazone.html http://www.rxlist.com/avandia-drug.htm http://www.wikidoc.org/index.php/Rosiglitazone

Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.

CNS Activity

Originator

Approval Year

1999
175
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 40.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
AVANDIA

Approved Use

After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS®) or pioglitazone-containing products (ACTOPLUS MET®, ACTOPLUS MET XR®, DUETACT®) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
598 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
432 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2971 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
2890 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.37 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
3.59 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
unhealthy, 53.1
Health Status: unhealthy
Age Group: 53.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
DLT: Headache, Malaise...
Disc. AE: Pain in leg...
Dose limiting toxicities:
Headache (3.1%)
Malaise (3.1%)
Oedema legs (9.4%)
AEs leading to
discontinuation/dose reduction:
Pain in leg (3.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Disc. AE: Macular edema...
AEs leading to
discontinuation/dose reduction:
Macular edema
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Disc. AE: Congestive heart failure, Myocardial ischemia...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Myocardial ischemia (2%)
Fluid retention
Edema
Weight gain
Anemia
Macular edema
Fracture bone
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Headache 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
unhealthy, 53.1
Health Status: unhealthy
Age Group: 53.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Malaise 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
unhealthy, 53.1
Health Status: unhealthy
Age Group: 53.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Pain in leg 3.1%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
unhealthy, 53.1
Health Status: unhealthy
Age Group: 53.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Oedema legs 9.4%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
unhealthy, 53.1
Health Status: unhealthy
Age Group: 53.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Macular edema Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Myocardial ischemia 2%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Anemia Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Congestive heart failure Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Fluid retention Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Fracture bone Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Macular edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Weight gain Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
PubMed

PubMed

TitleDatePubMed
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.
2005-10
Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1.
2005-09
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
2005-08
Rosiglitazone up-regulates lipoprotein lipase, hormone-sensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats.
2005-06
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.
2005-06
Fatty acids and expression of adipokines.
2005-05-30
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
2005-05-12
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.
2005-05
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
2005-05
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.
2005-05
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.
2005-05
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
2005-03
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
2005-03
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
2005-03
Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators.
2005-03
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
2005-03
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
2005-03
Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
2005-02
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.
2005-02
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
2005-02
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
2005-01
Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.
2005
The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes.
2005
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
2004-12-15
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
2004-12-01
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
2004-12
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
2004-12
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
2004-11
Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone.
2004-11
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004-11
Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation.
2004-10-22
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
2004-10
Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
2004-10
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
2004-09
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
2004-08
The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
2004-08
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.
2004-08
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.
2004-07-01
Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
2004-06-04
Evidence for a potent antiinflammatory effect of rosiglitazone.
2004-06
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.
2004-05-15
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.
2004-05
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
2004-04
Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
2004-04
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
2004-03-23
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
2004-03
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
2004-01-01
Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes.
2003-12
Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.
2003-12
Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
2003-12
Patents

Patents

06515132
8
JP2002543077A
8
JP2004536047A
26
JP2008195625A
8
JP2011252007A
8
JP4365554B2
24
JP4741458B2
8

Sample Use Guides

In Vivo Use Guide
Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Rosiglitazone treatment (5 uM) prevents NO and prostacyclin overproduction by inhibiting microparticles-induced iNOS and COX-2 expression.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:24:38 GMT 2025
Edited
by admin
on Mon Mar 31 18:24:38 GMT 2025
Record UNII
05V02F2KDG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROSIGLITAZONE
EMA EPAR   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
GAUDIL
Preferred Name English
ROSIGLIZOLE
Brand Name English
BRL-49653
Code English
NSC-758698
Code English
ROSIGLITAZONE [MI]
Common Name English
rosiglitazone [INN]
Common Name English
ROSIGLITAZONE [EMA EPAR]
Common Name English
REZULT
Brand Name English
TDZ-01
Code English
ROSIGLITAZONE [VANDF]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-
Systematic Name English
ROSIGLITAZONE [MART.]
Common Name English
ROSIGLITAZONE [IARC]
Common Name English
ROSVEL
Brand Name English
5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
ROSIGLITAZONE [HSDB]
Common Name English
Rosiglitazone [WHO-DD]
Common Name English
5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000011272
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-ATC A10BD03
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
LIVERTOX NBK548114
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000180190
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-ATC A10BD04
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-VATC QA10BG02
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000175374
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NCI_THESAURUS C1934
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-VATC QA10BD04
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-ATC A10BG02
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000170119
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000011272
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
WHO-VATC QA10BD03
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000180186
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000170119
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
NDF-RT N0000011272
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
Code System Code Type Description
SMS_ID
100000089168
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
EVMPD
SUB10388MIG
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
DRUG CENTRAL
2405
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
INN
7662
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
PUBCHEM
77999
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
HSDB
7555
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
DRUG BANK
DB00412
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
NSC
758698
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
LACTMED
Rosiglitazone
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
WIKIPEDIA
ROSIGLITAZONE
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
IUPHAR
1056
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
DAILYMED
05V02F2KDG
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
CHEBI
50122
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
MESH
C089730
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
NCI_THESAURUS
C62076
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
EPA CompTox
DTXSID7037131
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
MERCK INDEX
m9666
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY Merck Index
CAS
122320-73-4
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
ChEMBL
CHEMBL121
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
FDA UNII
05V02F2KDG
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY
RXCUI
84108
Created by admin on Mon Mar 31 18:24:38 GMT 2025 , Edited by admin on Mon Mar 31 18:24:38 GMT 2025
PRIMARY RxNorm
Related Record Type Details
OATP-8
TRANSPORTER -> INHIBITOR
OATP1B1
TRANSPORTER -> INHIBITOR
OATP-B
TRANSPORTER -> INHIBITOR
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET -> INHIBITOR
Binding Assay
IC50
Structure of ROSIGLITAZONE POTASSIUM
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
OCT-1
TRANSPORTER -> INHIBITOR
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (S)-
ENANTIOMER -> RACEMATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of Rosiglitazone tartrate
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE SODIUM
SALT/SOLVATE -> PARENT
Structure of [3H] Rosiglitazone
LABELED -> NON-LABELED
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE FUMARATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE CHOLINATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (R)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of N-DESMETHYL-O-HYDROXY ROSIGLITAZONE
METABOLITE INACTIVE -> PARENT
MINOR
Structure of P-HYDROXY ROSIGLITAZONE
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
Structure of ROSIGLITAZONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966